Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Ghada Malik"'
Autor:
Alan V. Boddy, Andrew D.J. Pearson, Ann K. Daly, Michael Cole, Ghada Malik, Nicola A. Illingworth, Sophie E. Rowbotham, Julie Errington, Gareth J. Veal
PDF file - 72K, Observed and fitted 13-cisRA data from four patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a4e2bc41b377f2d8d1a9ee8a3826532
https://doi.org/10.1158/1078-0432.22455344.v1
https://doi.org/10.1158/1078-0432.22455344.v1
Autor:
Alan V. Boddy, Andrew D.J. Pearson, Ann K. Daly, Michael Cole, Ghada Malik, Nicola A. Illingworth, Sophie E. Rowbotham, Julie Errington, Gareth J. Veal
PDF file - 43K, Relationship between 13-cisRA AUC0-6h and 13-cisRA Cmax determined from pharmacokinetic profiles obtained following protocol-based 13-cisRA dosing (n=103)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c6ed9912ffabfaae1260fd952fa157e2
https://doi.org/10.1158/1078-0432.22455341
https://doi.org/10.1158/1078-0432.22455341
Autor:
Alan V. Boddy, Andrew D.J. Pearson, Ann K. Daly, Michael Cole, Ghada Malik, Nicola A. Illingworth, Sophie E. Rowbotham, Julie Errington, Gareth J. Veal
PDF file - 46K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09c1c13e553d08bc50f6ca756690f615
https://doi.org/10.1158/1078-0432.22455338
https://doi.org/10.1158/1078-0432.22455338
Autor:
Alan V. Boddy, Andrew D.J. Pearson, Ann K. Daly, Michael Cole, Ghada Malik, Nicola A. Illingworth, Sophie E. Rowbotham, Julie Errington, Gareth J. Veal
Purpose: To investigate the feasibility of adaptive dosing and the impact of pharmacogenetic variation on 13-cis-retinoic acid (13-cisRA) disposition in high-risk patients with neuroblastoma.Experimental Design: 13-cisRA (160 mg/m2 or 5.33 mg/kg/d) w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3bc98a02fee16715283739104c8659fe
https://doi.org/10.1158/1078-0432.c.6522998.v1
https://doi.org/10.1158/1078-0432.c.6522998.v1
Autor:
Gareth J. Veal, Nicola A. Illingworth, Julie Errington, Ghada Malik, Michael Cole, Andrew D.J. Pearson, Sophie E. Rowbotham, Alan V. Boddy, Ann K. Daly
Publikováno v:
Clinical Cancer Research. 19:469-479
Purpose: To investigate the feasibility of adaptive dosing and the impact of pharmacogenetic variation on 13-cis-retinoic acid (13-cisRA) disposition in high-risk patients with neuroblastoma. Experimental Design: 13-cisRA (160 mg/m2 or 5.33 mg/kg/d)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::89beb1912ed8c0b74e8c56cd2a057849
https://doi.org/10.1158/1078-0432.ccr-12-2225
https://doi.org/10.1158/1078-0432.ccr-12-2225
Autor:
Julie, Errington, Ghada, Malik, Julie, Evans, Jenny, Baston, Annie, Parry, Lisa, Price, Hina, Johnstone, Selena, Peters, Victoria, Oram, Karen, Howe, Emma, Whiteley, Jane, Tunnacliffe, Gareth J, Veal
Publikováno v:
Pediatric Blood & Cancer
Background While the majority of childhood cancer clinical trials are treatment related, additional optional research investigations may be carried out that do not directly impact on treatment. It is essential that these studies are conducted ethical
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::423fcf020d2d35e13bc3e944ff6e342a
https://pubmed.ncbi.nlm.nih.gov/26928983
https://pubmed.ncbi.nlm.nih.gov/26928983
Publikováno v:
Transplantation. 79:672-679
Background Chemokines recruit leukocytes during allograft rejection. It is thought that the formation of glycosaminoglycan (GAG)-stabilized chemokine concentration gradients within the allograft plays a crucial role in this process. This raises the p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f60ae743560d54b9f7b29700e238776
https://doi.org/10.1097/01.tp.0000155961.57664.db
https://doi.org/10.1097/01.tp.0000155961.57664.db
Autor:
Gareth J. Veal, Julie Errington, Christopher R. Hill, Michael Cole, Ghada Malik, Alan V. Boddy
Publikováno v:
Clinical Pharmacokinetics
Background and Objective Despite its important role in cancer treatment, there is currently very limited available information concerning the clinical pharmacology of actinomycin D (Act D). The study was designed to characterise Act D pharmacokinetic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc0a461544c947e3a5485a755d9cdb4f
https://pubmed.ncbi.nlm.nih.gov/24968986
https://pubmed.ncbi.nlm.nih.gov/24968986
Publikováno v:
Journal of immunology (Baltimore, Md. : 1950). 175(2)
A non-glycosaminoglycan (GAG)-binding variant of the pleiotropic chemokine CCL7 was generated by mutating to alanine the basic (B) amino acids within an identified 44BXBXXB49 GAG-binding motif. Unlike wild-type (wt) CCL7, the mutant sequence had no a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::741bf03b2d3cffcf2f1535512c071893
https://pubmed.ncbi.nlm.nih.gov/16002730
https://pubmed.ncbi.nlm.nih.gov/16002730
Autor:
Gareth J. Veal, Ghada Malik, Julie Errington, Alan V. Boddy, Michael D. Cole, Christopher R. Hill
Publikováno v:
Cancer Research. 74:4651-4651
Actinomycin D (Act D) is an anti-tumor antibiotic commonly used in the treatment of cancer in children and adults. As part of a multimodal approach, Act D is a key component in the treatment of Wilms tumor, where cure rates as high as 90% have been a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::764fe1cbaa24a3b742086dd44044411d
https://doi.org/10.1158/1538-7445.am2014-4651
https://doi.org/10.1158/1538-7445.am2014-4651